Taris gets $12.5 million for bladder drug delivery candidate; Pfizer joins BIND for nanoparticle delivery;

> Taris Biomedical snagged $12.5 million in funding for its LiRIS candidate that delivers drugs directly to the bladder. 

> Pfizer ($PFE) inked a deal with BIND Biosciences, a Robert Langer venture, to get a piece of the nanoparticle drug delivery market. More

> Eli Lilly ($LLY) is pumping money into its facility devoted to filling insulin cartridges, investing $180 million in the plant, adding to the $140 million added last year. Story

> Researchers at the Johns Hopkins University School of Medicine have found that sublingual delivery of allergens could be effective for patients with allergic rhinitis. Article

> The FDA approved Tris Pharma's extended-release option for Karbinal, a drug to treat allergic rhinitis, in oral delivery form. Release

> Oramed ($ORMP) snagged Japanese approval of its patent on the oral delivery of proteins. Release

> A compound, cyclodextrin, used as an ingredient in other drugs is undergoing tests to determine whether it will improve other treatments by helping with the delivery of cholesterol to the brain. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.